BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 18084326)

  • 1. The EWS/FLI1 oncogenic transcription factor deregulates GLI1.
    Zwerner JP; Joo J; Warner KL; Christensen L; Hu-Lieskovan S; Triche TJ; May WA
    Oncogene; 2008 May; 27(23):3282-91. PubMed ID: 18084326
    [TBL] [Abstract][Full Text] [Related]  

  • 2. GLI1 is a central mediator of EWS/FLI1 signaling in Ewing tumors.
    Joo J; Christensen L; Warner K; States L; Kang HG; Vo K; Lawlor ER; May WA
    PLoS One; 2009 Oct; 4(10):e7608. PubMed ID: 19859563
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Divergent Ewing's sarcoma EWS/ETS fusions confer a common tumorigenic phenotype on NIH3T3 cells.
    Thompson AD; Teitell MA; Arvand A; Denny CT
    Oncogene; 1999 Sep; 18(40):5506-13. PubMed ID: 10523827
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BET bromodomain inhibitors suppress EWS-FLI1-dependent transcription and the IGF1 autocrine mechanism in Ewing sarcoma.
    Loganathan SN; Tang N; Fleming JT; Ma Y; Guo Y; Borinstein SC; Chiang C; Wang J
    Oncotarget; 2016 Jul; 7(28):43504-43517. PubMed ID: 27259270
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FOXM1 is an oncogenic mediator in Ewing Sarcoma.
    Christensen L; Joo J; Lee S; Wai D; Triche TJ; May WA
    PLoS One; 2013; 8(1):e54556. PubMed ID: 23365673
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A zebrafish transgenic model of Ewing's sarcoma reveals conserved mediators of EWS-FLI1 tumorigenesis.
    Leacock SW; Basse AN; Chandler GL; Kirk AM; Rakheja D; Amatruda JF
    Dis Model Mech; 2012 Jan; 5(1):95-106. PubMed ID: 21979944
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A molecular function map of Ewing's sarcoma.
    Kauer M; Ban J; Kofler R; Walker B; Davis S; Meltzer P; Kovar H
    PLoS One; 2009; 4(4):e5415. PubMed ID: 19404404
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transactivation of cyclin E gene by EWS-Fli1 and antitumor effects of cyclin dependent kinase inhibitor on Ewing's family tumor cells.
    Li X; Tanaka K; Nakatani F; Matsunobu T; Sakimura R; Hanada M; Okada T; Nakamura T; Iwamoto Y
    Int J Cancer; 2005 Sep; 116(3):385-94. PubMed ID: 15818598
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FOXO1 is a direct target of EWS-Fli1 oncogenic fusion protein in Ewing's sarcoma cells.
    Yang L; Hu HM; Zielinska-Kwiatkowska A; Chansky HA
    Biochem Biophys Res Commun; 2010 Nov; 402(1):129-34. PubMed ID: 20933505
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NR0B1 is required for the oncogenic phenotype mediated by EWS/FLI in Ewing's sarcoma.
    Kinsey M; Smith R; Lessnick SL
    Mol Cancer Res; 2006 Nov; 4(11):851-9. PubMed ID: 17114343
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EWS/FLI mediates transcriptional repression via NKX2.2 during oncogenic transformation in Ewing's sarcoma.
    Owen LA; Kowalewski AA; Lessnick SL
    PLoS One; 2008 Apr; 3(4):e1965. PubMed ID: 18414662
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PDGF-C is an EWS/FLI induced transforming growth factor in Ewing family tumors.
    Zwerner JP; May WA
    Oncogene; 2001 Feb; 20(5):626-33. PubMed ID: 11313995
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Caveolin-1 (CAV1) is a target of EWS/FLI-1 and a key determinant of the oncogenic phenotype and tumorigenicity of Ewing's sarcoma cells.
    Tirado OM; Mateo-Lozano S; Villar J; Dettin LE; Llort A; Gallego S; Ban J; Kovar H; Notario V
    Cancer Res; 2006 Oct; 66(20):9937-47. PubMed ID: 17047056
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel role for keratin 17 in coordinating oncogenic transformation and cellular adhesion in Ewing sarcoma.
    Sankar S; Tanner JM; Bell R; Chaturvedi A; Randall RL; Beckerle MC; Lessnick SL
    Mol Cell Biol; 2013 Nov; 33(22):4448-60. PubMed ID: 24043308
    [TBL] [Abstract][Full Text] [Related]  

  • 15. GLI1 is a direct transcriptional target of EWS-FLI1 oncoprotein.
    Beauchamp E; Bulut G; Abaan O; Chen K; Merchant A; Matsui W; Endo Y; Rubin JS; Toretsky J; Uren A
    J Biol Chem; 2009 Apr; 284(14):9074-82. PubMed ID: 19189974
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting CD99 Compromises the Oncogenic Effects of the Chimera EWS-FLI1 by Inducing Reexpression of Zyxin and Inhibition of GLI1 Activity.
    Balestra T; Manara MC; Laginestra MA; Pasello M; De Feo A; Bassi C; Guerzoni C; Landuzzi L; Lollini PL; Donati DM; Negrini M; Magnani M; Scotlandi K
    Mol Cancer Ther; 2022 Jan; 21(1):58-69. PubMed ID: 34667115
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inducible expression of chimeric EWS/ETS proteins confers Ewing's family tumor-like phenotypes to human mesenchymal progenitor cells.
    Miyagawa Y; Okita H; Nakaijima H; Horiuchi Y; Sato B; Taguchi T; Toyoda M; Katagiri YU; Fujimoto J; Hata J; Umezawa A; Kiyokawa N
    Mol Cell Biol; 2008 Apr; 28(7):2125-37. PubMed ID: 18212050
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EWS/FLI and its downstream target NR0B1 interact directly to modulate transcription and oncogenesis in Ewing's sarcoma.
    Kinsey M; Smith R; Iyer AK; McCabe ER; Lessnick SL
    Cancer Res; 2009 Dec; 69(23):9047-55. PubMed ID: 19920188
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DNA binding domain-independent pathways are involved in EWS/FLI1-mediated oncogenesis.
    Welford SM; Hebert SP; Deneen B; Arvand A; Denny CT
    J Biol Chem; 2001 Nov; 276(45):41977-84. PubMed ID: 11553628
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EWS-FLI1 in Ewing's sarcoma: real targets and collateral damage.
    Ban J; Siligan C; Kreppel M; Aryee D; Kovar H
    Adv Exp Med Biol; 2006; 587():41-52. PubMed ID: 17163154
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.